Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CATX | PRESS-RELEASE | neutral | 3/10 | Perspective Therapeutics announced first patient dosing in two new cohorts of its Phase 1/2a trials for [212Pb]VMT-α-NET | May 18, 2026 |
| GLAXF | 6-K | bullish | 6/10 | GSK announced that Japan's MHLW expanded approval of its RSV vaccine Arexvy to include adults aged 18-49 at increased ri | May 18, 2026 |
| JBIO | EFFECT | bearish | 7/10 | Two S-3 shelf registrations for Jade Biosciences became effective on May 15, 2026. File No. 333-295662 covers a resale o | May 18, 2026 |
| ENTX | EFFECT | neutral | 3/10 | The SEC declared effective Entera Bio's S-3 registration statement (File No. 333-295710) on May 15, 2026, covering the r | May 18, 2026 |
| TRAW | EFFECT | bearish | 7/10 | Traws Pharma's S-3 shelf registration (File No. 333-295727) became effective on May 15, 2026, enabling selling stockhold | May 18, 2026 |
| NCEL | EFFECT | bearish | 5/10 | NewcelX Ltd.'s F-3 shelf registration (File No. 333-295770) became effective on May 15, 2026, allowing the company to of | May 18, 2026 |
| QNTM | 6-K | bullish | 6/10 | Quantum BioPharma announced that its collaborative imaging study with Massachusetts General Hospital has reached the mid | May 18, 2026 |
| NBTX | 6-K | bullish | 7/10 | Nanobiotix announced Part 1 data from the CONVERGE Phase 2 trial of JNJ-1900 (NBTXR3) in stage 3 inoperable NSCLC, prese | May 18, 2026 |
| XFOR | EFFECT | neutral | 4/10 | X4 Pharmaceuticals' S-3 shelf registration (File No. 333-295597) became effective on May 14, 2026, enabling the company | May 18, 2026 |
| DSGN | PRESS-RELEASE | bullish | 8/10 | Design Therapeutics will announce Phase 1/2 RESTORE-FA trial data for DT-216P2 in Friedreich's ataxia on May 18, 2026. T | May 17, 2026 |
| NBTX | PRESS-RELEASE | bullish | 7/10 | Nanobiotix announced Part 1 data from the Johnson & Johnson-sponsored Phase 2 CONVERGE study of NBTXR3 (JNJ-1900) in sta | May 17, 2026 |
| REGN | PRESS-RELEASE | bearish | 7/10 | Regeneron announced that its Phase 3 trial of fianlimab (LAG-3 inhibitor) plus cemiplimab in first-line melanoma did not | May 15, 2026 |
| APGE | CLUSTER | neutral | 3/10 | CEO Michael Thomas Henderson sold $1.53M worth of APGE stock on May 13, 2026, and CMO Carl Dambkowski sold $311K on May | May 15, 2026 |
| PLSE | CLUSTER | bullish | 7/10 | Two insiders at Pulse Biosciences, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market | May 15, 2026 |
| LQDA | CLUSTER | neutral | 3/10 | CEO Roger Jeffs and Director Stephen Bloch sold a combined $5.15M in open-market sales over a 5-day window, representing | May 15, 2026 |
| RNXT | 10-K/A | neutral | 4/10 | RenovoRx filed Amendment No. 1 to its 2025 10-K solely to revise risk factor disclosures (Item 1A) and add missing contr | May 15, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Two PTCT insiders, including CEO Matthew Klein, sold a combined ~$115K in open-market sales within a week of the company | May 15, 2026 |
| PMHS | 8-K | mixed | 6/10 | Polomar Health Services and Altanine waived five key closing conditions for their merger, including the S-4 effectivenes | May 15, 2026 |
| HURA | 8-K | neutral | 4/10 | TuHURA Biosciences reported Q1 2026 financial results with no revenue and a net loss per share of -$0.17, missing the co | May 15, 2026 |
| SNYR | S-1 | bearish | 7/10 | Synergy CHC filed an S-1 registration for the resale of up to 101.71 million shares by selling stockholder Hudson Global | May 15, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Four UTHR insiders (CEO, CFO, EVP, Director) sold a total of ~$1.04M in open-market sales over a 7-day window following | May 15, 2026 |
| INSM | S-3ASR | neutral | 3/10 | Insmed filed an automatic shelf registration (S-3ASR) covering an indeterminate amount of common stock and debt securiti | May 15, 2026 |
| BCLI | 8-K | bearish | 6/10 | BrainStorm Cell Therapeutics reported Q1 2026 results with a net loss of $2.1M ($0.19 per share), narrower than the $2.9 | May 15, 2026 |
| ZYME | 3 | neutral | 2/10 | Form 3 filing for Paul R. Schneider, EVP and General Counsel of Zymeworks Inc., reports zero beneficial ownership. This | May 15, 2026 |
| CTOR | 8-K | mixed | 6/10 | Citius Oncology reported fiscal Q2 2026 (March 31, 2026) net product revenue of $1.7M, down from $3.9M in Q1 due to init | May 15, 2026 |
| CTXR | 8-K | bearish | 6/10 | Citius Pharmaceuticals reported Q2 fiscal 2026 revenue of $1.7M (vs $0 a year ago) from LYMPHIR sales, but net loss wide | May 15, 2026 |
| RPRX | CLUSTER | neutral | 3/10 | Two insiders at Royalty Pharma sold a combined $888K in open-market sales on May 14, 2026, following the company's Q1 ea | May 15, 2026 |
| OPK | DEFA14A | neutral | 4/10 | OPKO Health filed a DEFA14A supplement clarifying that its 2016 Equity Incentive Plan expired in February 2026, renderin | May 15, 2026 |
| SLXNW | 8-K | bearish | 7/10 | Silexion Therapeutics entered into an inducement letter with holders of 1,995,092 existing warrants (Series A, B, and Pr | May 15, 2026 |
| ADTX | 8-K | neutral | 4/10 | Aditxt announced a 1-for-27 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. The sp | May 15, 2026 |